In mice implanted with HeLa229 TR/CRISPR cells, paclitaxel monotherapy significantly inhibited tumor growth and recurrence, suggesting that silencing of MUC1 sufficiently increased sensitivity of tumors to paclitaxel (Fig. 4a; Supplementary Fig. S6E). Here, MUC1 is linked to neoplasm.